Invivotek
About Invivotek
Invivotek offers both custom and standard preclinical services for drug discovery and development programs for their clients in the areas of autoimmune and inflammatory disease, immuno-oncology, and metabolic disease. Invivotek's experience across multiple therapeutic areas and its efficient project management positions the company as a leading provider of preclinical in vivo services. Together with its sister CRO companies Venenum Biodesign and PharmOptima, Invivotek offers a comprehensive portfolio of services from drug target discovery through pre-clinical candidate selection through GBG's VIP Drug Discovery Services.
YEAR FOUNDED:
2012
LEADERSHIP:
CSO: Olesia Buiakova
2 articles about Invivotek
-
Genesis Drug Discovery & Development Appoints Olesia Buiakova, M.D., Ph.D., as Chief Scientific Officer
7/19/2018
Genesis Drug Discovery & Development has announced the appointment of Olesia Buiakova, M.D., Ph.D., the Chief Scientific Officer of Invivotek as its new Chief Scientific Officer.
-
Invivotek Maintains Full AAALAC Accreditation For Excellence In Animal Care And Use
9/15/2017